AGRN

agrin, the group of Proteoglycans

Basic information

Region (hg38): 1:1020120-1056119

Previous symbols: [ "AGRIN" ]

Links

ENSG00000188157NCBI:375790OMIM:103320HGNC:329Uniprot:O00468AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • congenital myasthenic syndrome 8 (Strong), mode of inheritance: AR
  • congenital myasthenic syndrome 8 (Strong), mode of inheritance: AR
  • postsynaptic congenital myasthenic syndrome (Supportive), mode of inheritance: AR
  • presynaptic congenital myasthenic syndrome (Supportive), mode of inheritance: AD
  • congenital myasthenic syndrome 8 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Myasthenic syndrome, congenital 8ARMusculoskeletal; Neurologic; PharmacogenomicEphedrine treatment has been reported as effective in affected inviduals; Medical treatment with acetylcholine esterase inhibitors and/or potassium channel blocker 3,4-diaminopyridine may be beneficial in many individuals; In infancy, the use of apnea monitors may be indicated; Agents that affect neuromuscular transmission and exacerbate myasthenic manifestations should be avoidedMusculoskeletal; Neurologic19631309; 20301347; 22205389; 22678886

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the AGRN gene.

  • Congenital myasthenic syndrome 8 (24 variants)
  • Abnormality of the musculature (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the AGRN gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
11
clinvar
598
clinvar
20
clinvar
629
missense
3
clinvar
946
clinvar
44
clinvar
6
clinvar
999
nonsense
8
clinvar
2
clinvar
2
clinvar
12
start loss
0
frameshift
17
clinvar
4
clinvar
21
inframe indel
16
clinvar
16
splice donor/acceptor (+/-2bp)
11
clinvar
11
splice region
1
40
69
4
114
non coding
6
clinvar
247
clinvar
82
clinvar
335
Total 25 20 981 889 108

Highest pathogenic variant AF is 0.0000525

Variants in AGRN

This is a list of pathogenic ClinVar variants found in the AGRN region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
1-1020177-C-A Congenital myasthenic syndrome 8 Uncertain significance (Jan 15, 2024)474165
1-1020182-C-T Congenital myasthenic syndrome 8 Uncertain significance (Jul 09, 2020)2438920
1-1020183-G-C Congenital myasthenic syndrome 8 • AGRN-related disorder Benign (Jan 26, 2024)387476
1-1020192-C-G Congenital myasthenic syndrome 8 Uncertain significance (Jul 19, 2022)1519726
1-1020192-C-T Congenital myasthenic syndrome 8 Uncertain significance (Mar 01, 2022)1500704
1-1020193-G-T Congenital myasthenic syndrome 8 Likely benign (Nov 12, 2022)2018792
1-1020195-G-C Congenital myasthenic syndrome 8 Uncertain significance (May 10, 2022)2177809
1-1020196-C-T Congenital myasthenic syndrome 8 Likely benign (Feb 27, 2023)2869323
1-1020196-CCCGCTGCGG-C Congenital myasthenic syndrome 8 Uncertain significance (May 18, 2022)1913837
1-1020199-G-A Congenital myasthenic syndrome 8 Likely benign (Mar 09, 2022)1142839
1-1020200-C-A Congenital myasthenic syndrome 8 Uncertain significance (Mar 18, 2022)1007441
1-1020200-C-T Congenital myasthenic syndrome 8 Likely benign (Dec 22, 2019)1087083
1-1020204-G-A Congenital myasthenic syndrome 8 Uncertain significance (Jul 30, 2023)2965992
1-1020204-G-T Inborn genetic diseases Uncertain significance (Sep 01, 2021)2226520
1-1020204-G-GGCCGCTGCT Congenital myasthenic syndrome 8 Uncertain significance (Jan 09, 2024)574825
1-1020206-C-T Congenital myasthenic syndrome 8 Uncertain significance (Mar 26, 2022)1903344
1-1020208-G-A Congenital myasthenic syndrome 8 Likely benign (Nov 04, 2023)3010315
1-1020208-G-C Congenital myasthenic syndrome 8 Likely benign (Mar 18, 2022)1621463
1-1020209-C-G Congenital myasthenic syndrome 8 Uncertain significance (Mar 08, 2022)1414452
1-1020216-C-G Uncertain significance (May 19, 2020)377270
1-1020216-C-T Congenital myasthenic syndrome 8 Uncertain significance (Aug 31, 2021)1425556
1-1020216-CG-GT Congenital myasthenic syndrome 8 Uncertain significance (Oct 24, 2022)541157
1-1020217-G-T not specified • Congenital myasthenic syndrome 8 Benign (Feb 01, 2024)128310
1-1020220-C-T Congenital myasthenic syndrome 8 Likely benign (Jan 26, 2024)2710387
1-1020221-C-T Congenital myasthenic syndrome 8 Uncertain significance (Mar 26, 2022)388958

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
AGRNprotein_codingprotein_codingENST00000379370 3635994
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
5.47e-71.001255660641256300.000255
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.22613031.33e+30.9830.000099512779
Missense in Polyphen342394.870.866113727
Synonymous-3.967276031.200.00004964373
Loss of Function6.012990.90.3190.00000500963

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0007150.000702
Ashkenazi Jewish0.0004110.000397
East Asian0.0001660.000163
Finnish0.000.00
European (Non-Finnish)0.0003200.000299
Middle Eastern0.0001660.000163
South Asian0.0001370.000131
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Isoform 1: heparan sulfate basal lamina glycoprotein that plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ) and directs key events in postsynaptic differentiation. Component of the AGRN-LRP4 receptor complex that induces the phosphorylation and activation of MUSK. The activation of MUSK in myotubes induces the formation of NMJ by regulating different processes including the transcription of specific genes and the clustering of AChR in the postsynaptic membrane. Calcium ions are required for maximal AChR clustering. AGRN function in neurons is highly regulated by alternative splicing, glycan binding and proteolytic processing. Modulates calcium ion homeostasis in neurons, specifically by inducing an increase in cytoplasmic calcium ions. Functions differentially in the central nervous system (CNS) by inhibiting the alpha(3)- subtype of Na+/K+-ATPase and evoking depolarization at CNS synapses. This secreted isoform forms a bridge, after release from motor neurons, to basal lamina through binding laminin via the NtA domain.; FUNCTION: Isoform 1, isoform 4 and isoform 5: neuron-specific (z+) isoforms that contain C-terminal insertions of 8-19 AA are potent activators of AChR clustering. Isoform 5, agrin (z+8), containing the 8-AA insert, forms a receptor complex in myotubules containing the neuronal AGRN, the muscle-specific kinase MUSK and LRP4, a member of the LDL receptor family. The splicing factors, NOVA1 and NOVA2, regulate AGRN splicing and production of the 'z' isoforms.; FUNCTION: Agrin N-terminal 110 kDa subunit: is involved in regulation of neurite outgrowth probably due to the presence of the glycosaminoglcan (GAG) side chains of heparan and chondroitin sulfate attached to the Ser/Thr- and Gly/Ser-rich regions. Also involved in modulation of growth factor signaling (By similarity). {ECO:0000250, ECO:0000269|PubMed:19631309, ECO:0000269|PubMed:21969364}.;
Disease
DISEASE: Myasthenic syndrome, congenital, 8 (CMS8) [MIM:615120]: A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS8 is an autosomal recessive disease characterized by prominent defects of both the pre- and postsynaptic regions. Affected individuals have onset of muscle weakness in early childhood; the severity of the weakness and muscles affected is variable. {ECO:0000269|PubMed:19631309, ECO:0000269|PubMed:22205389, ECO:0000269|PubMed:24951643}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
ECM-receptor interaction - Homo sapiens (human);Primary Focal Segmental Glomerulosclerosis FSGS;Splicing factor NOVA regulated synaptic proteins;Developmental Biology;Signaling by GPCR;Signal Transduction;Metabolism of fat-soluble vitamins;Metabolism of carbohydrates;A tetrasaccharide linker sequence is required for GAG synthesis;HS-GAG biosynthesis;HS-GAG degradation;Heparan sulfate/heparin (HS-GAG) metabolism;Integrin cell surface interactions;Chondroitin sulfate/dermatan sulfate metabolism;Glycosaminoglycan metabolism;Extracellular matrix organization;Metabolism;Metabolism of vitamins and cofactors;Integrin;role of nicotinic acetylcholine receptors in the regulation of apoptosis;agrin in postsynaptic differentiation;NCAM signaling for neurite out-growth;Retinoid metabolism and transport;NCAM1 interactions;Non-integrin membrane-ECM interactions;G alpha (i) signalling events;Axon guidance;Visual phototransduction;ECM proteoglycans;GPCR downstream signalling;Wnt Canonical;Wnt Mammals (Consensus)

Recessive Scores

pRec
0.645

Intolerance Scores

loftool
0.421
rvis_EVS
-0.22
rvis_percentile_EVS
37.33

Haploinsufficiency Scores

pHI
0.402
hipred
Y
hipred_score
0.637
ghis
0.573

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.883

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Agrn
Phenotype
growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);

Zebrafish Information Network

Gene name
agrn
Affected structure
CaP motoneuron
Phenotype tag
abnormal
Phenotype quality
decreased length

Gene ontology

Biological process
retinoid metabolic process;glycosaminoglycan biosynthetic process;glycosaminoglycan catabolic process;cytoskeleton organization;signal transduction;G protein-coupled acetylcholine receptor signaling pathway;extracellular matrix organization;receptor clustering;positive regulation of GTPase activity;clustering of voltage-gated sodium channels;positive regulation of synaptic growth at neuromuscular junction;positive regulation of transcription by RNA polymerase II;synapse organization;positive regulation of filopodium assembly
Cellular component
extracellular region;basement membrane;Golgi lumen;cytosol;plasma membrane;integral component of membrane;cell junction;lysosomal lumen;synapse;collagen-containing extracellular matrix;extracellular exosome
Molecular function
dystroglycan binding;structural constituent of cytoskeleton;extracellular matrix structural constituent;calcium ion binding;protein binding;sialic acid binding;chondroitin sulfate binding;laminin binding;heparan sulfate proteoglycan binding